1083326-55-9

Basic information

• Product Name: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%
• Synonyms: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%;N-[2-CHLORO-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-BENZENESULFONAMIDE
• CAS NO: 1083326-55-9
• Molecular Formula: C₁₇H₂₀BClN₂O₄S
• Molecular Weight: 412.69598
• Mol File: 1083326-55-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%(1083326-55-9)
• EPA Substance Registry System: 2-Chloro-3-phenylsulfonaMidopyridine-5-boronic acid pinacol ester, 96%(1083326-55-9)

Safety Data

• Hazardous Substances Data: 1083326-55-9(Hazardous Substances Data)

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 588729-99-1 3-amino-5-bromo-2-chloropyridine 
• 15862-34-7 5-bromo-3-nitro-1H-pyridin-2-one 
• 1083326-17-3 N-(5-bromo-2-chloropyridin-3-yl)benzenesulfonamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1092565-28-0 N-(2-chloro-5-{8-[3-(methylsulfonyl)phenyl]-1,5-naphthyridin-2-yl}-3-pyridinyl)benzenesulfonamide 
• 1092565-27-9 N-{2-chloro-5-[8-(4-pyridinyl)-1,5-naphthyridin-2-yl]-3-pyridinyl}benzenesulfonamide 
• 1135310-06-3 N-(2-chloro-5-(4-(4-morpholinyl)pyrido[3,2-d]pyrimidin-6-yl)-3-pyridinyl)benzenesulfonamide 
• 1400667-75-5 N-(2-chloro-5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1148008-27-8 N-[2-chloro-5-(quinolin-3-yl)pyridin-3-yl]benzenesulfonamide 
• 1148008-15-4 N-[5-(6-aminopyridin-3-yl)-2-chloropyridin-3-yl]benzenesulfonamide 
• 1093818-79-1 N-(2-chloro-5-(quinazolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1148008-46-1 N-{2-chloro-5-[3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-6-yl]-3-pyridinyl}benzenesulfonamide 
• 1148008-29-0 N-[5-(2-amino-5-pyrimidinyl)-2-chloro-3-pyridinyl]benzenesulfonamide 

Relevant articles and documents

Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation

Based on indole scaffold, a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, namely FD223, was developed by the bioisosteric replacement drug discovery approach and studied for the treatment of acute myeloid leukemia (AML). In vitro

Cnoline compound PI3K kinase inhibitor as well as preparation method and application thereof in pharmacy

The invention provides a cinnoline compound PI3K kinase inhibitor as shown in a formula I. In the cinnoline compound PI3K kinase inhibitor, and R1, R2 and R3 are defined in the specification. The invention also provides a pharmaceutical composition of the

Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation

Breast cancer is the cancer with the highest incidence all over the world. Phosphatidylinositol 3-kinase is an important regulator of intracellular signaling pathways, which is frequently mutated and overexpressed in majority of human breast cancers, and the inhibition of PI3K has been considered as a promising approach for the treatment of the cancer. Here, we report our design and synthesis of new 7-azaindole derivatives as PI3K inhibitors through the scaffold hopping strategy. By varying the groups at the 3-position of 7-azaindole, we identified a series of potent PI3K inhibitors, whose antiproliferative activities against two human breast cancer MCF-7 and MDA-MB-231 cell lines were evaluated. Representative derivatives FD2054 and FD2078 showed better activity than BKM120 in antiproliferation, reduced the levels of phospho-AKT and induced cell apoptosis. All these results suggested that FD2054 and FD2078 are potent PI3K inhibitors that could be considered as potential candidates for the development of anticancer agents.

Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity

Cinnoline is a potential pharmacophore which has rarely been reported for uses as PI3K inhibitors. In this study, a series of cinnoline derivatives were developed as PI3K inhibitors and evaluated for enzymatic and cellular activities. Most compounds displ

Micro-reactor tandem synthesis method of indole anticancer drug molecules

The invention relates to a micro-reactor tandem synthesis method of indole anticancer drug molecules. The method comprises the following steps: a reaction liquid 1 and a reaction liquid 2 are mixed, then are introduced into a first micro-reactor, and are reacted to obtain a first effluent, the first effluent and a reaction liquid 3 are mixed, then are introduced into a second micro-reactor, and are reacted to obtain a second effluent, the second effluent and a reaction liquid 4 are mixed, then are introduced into a third micro-reactor, and are reacted to obtain a final effluent, and the finaleffluent is concentrated and separated to obtain the indole anticancer drug molecules, wherein the reaction liquid 1 is a mixed solution containing 5-bromine-3-amino-2-substituted (R1)-pyridine, the reaction liquid 2 is substituted (R2)-benzenesulfonyl chloride, the reaction liquid 3 is a mixed solution containing bis(pinacolato)diboron, the reaction liquid 4 is a mixed solution containing a 5-bromo-7-azaindole derivative, and the indole anticancer drug molecules are benzenesulfonamidopyridylazaindole compounds. Compared with the prior art, the method of the invention has the advantages of high reaction efficiency, few side reactions and simple production process.

PI3K inhibitor, preparation method and application thereof in pharmacy

The invention belongs to the technical field of pharmaceuticals and particularly relates to a PI3K inhibitor, a preparation method and application thereof in the pharmacy. The PI3K inhibitor is a compound of the structure shown by the general formula I or medically acceptable salt of the inhibitor. After the PI3K inhibitor is tested with a PI3K biochemical activity test method, the compound has excellent inhibitory activity to PI3K alpha and PI3K gamma, wherein the IC50 values of a plurality of compounds to the PI3K alpha and PI3K gamma reach nanomole grades (smaller than 100 nM). The result shows that the compounds can provide the inhibitor with better effectiveness and selectivity for curing PI3K-acted proliferative disease, and further a targeted drug for curing No. I type diabetes mellitus, lung disease, breast cancer, prostatic cancer, solid tumor, lymphoma, cardiovascular disease, rheumatoid arthritis, leukemia and the like can be hopefully developed. (Please see the general formula I in the description.).

NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.

PYRIDOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using pyridoprimidine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridopyrimidine derivatives.

PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridosulfonamide derivatives.

QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.